VolitionRX (AMEX:VNRX) Is Now Covered By Maxim Group. What can We Expect?

May 17, 2018 - By Clifton Ray

VolitionRx Limited (NYSEAMERICAN:VNRX) Logo

Investors sentiment decreased to 1.2 in Q4 2017. Its down 5.80, from 7 in 2017Q3. It is negative, as 3 investors sold VolitionRx Limited shares while 2 reduced holdings. 2 funds opened positions while 4 raised stakes. 4.52 million shares or 51.36% less from 9.30 million shares in 2017Q3 were reported.

Blackrock holds 0% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX) for 11,219 shares. Garrison Bradford And Associate holds 0.04% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX) for 15,500 shares. Geode Capital Ltd Liability Com owns 100,890 shares. Comml Bank Of New York Mellon holds 10,335 shares. 351,538 were accumulated by Knoll Cap Limited Partnership. 10,000 were accumulated by Bessemer Group Inc. 204,994 are owned by Vanguard Gp. Brown Brothers Harriman & invested in 0% or 3,823 shares. Northern invested 0% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX). Lagoda Inv Management Limited Partnership, New York-based fund reported 3.52 million shares. Bridgeway Cap Mngmt Incorporated stated it has 0% of its portfolio in VolitionRx Limited (NYSEAMERICAN:VNRX). Morgan Stanley holds 63,400 shares or 0% of its portfolio. Creative Planning holds 0% or 13,200 shares in its portfolio. 14,007 are owned by Royal Bancorp Of Canada. Leisure Capital holds 0.18% or 74,863 shares in its portfolio.

Why Has Maxim Group Given VolitionRX (AMEX:VNRX) a $6.0000 Price Target

Maxim Group has just issued a Buy rating for VolitionRX (AMEX:VNRX) shares. The firm has begun coverage on shares of VNRX in analysts report sent to investors and clients on 16 May. This target price would suggest upside of 166.67 % from the last price of VolitionRX (AMEX:VNRX).

The stock increased 8.70% or $0.18 during the last trading session, reaching $2.25. About 145,762 shares traded or 4.78% up from the average. VolitionRx Limited (AMEX:VNRX) has declined 42.82% since May 17, 2017 and is downtrending. It has underperformed by 54.37% the S&P500.

Analysts await VolitionRx Limited (NYSEAMERICAN:VNRX) to report earnings on August, 8. They expect $-0.17 EPS, down 30.77 % or $0.04 from last year’s $-0.13 per share. After $-0.17 actual EPS reported by VolitionRx Limited for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers. The company has market cap of $67.57 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It currently has negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.